MEREO BIOPHARMA GROUP PLC Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
MEREO BIOPHARMA GROUP PLC (MREO) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $806.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $577.00K, a 70.10% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $229.00K.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$2.26M.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$673.00K.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$2.39M.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$1.19M.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$710.00K, a 184.12% decline from fiscal 2022.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $844.00K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $577.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $806.00K 10-Q · filed 2026-08-11 | -$1.46M derived: sum of 3 quarters · filed 2026-08-11 | -$2.13M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $229.00K 10-Q · filed 2026-05-12 | -$2.03M derived: sum of 2 quarters · filed 2026-05-12 | -$2.71M derived: sum of 3 quarters · filed 2026-05-12 | -$775.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$2.93M derived: sum of 2 quarters · filed 2026-03-19 | -$1.00M derived: sum of 3 quarters · filed 2026-08-11 | -$2.39M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$673.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.26M derived: sum of 2 quarters · filed 2026-08-11 | -$133.00K 10-Q · filed 2025-11-10 | -$839.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $540.00K 10-Q · filed 2026-08-11 | -$166.00K derived: sum of 3 quarters · filed 2026-08-11 | -$958.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$1.39M 10-Q · filed 2026-05-12 | -$2.10M derived: sum of 2 quarters · filed 2026-05-12 | -$2.89M derived: sum of 3 quarters · filed 2026-05-12 | $357.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$706.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$1.50M derived: sum of 2 quarters · filed 2026-03-19 | $1.75M derived: sum of 3 quarters · filed 2026-03-19 | -$1.19M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$792.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.45M derived: sum of 2 quarters · filed 2025-11-10 | -$486.00K 10-Q · filed 2025-11-10 | -$2.20M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $3.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $306.00K 10-Q · filed 2025-08-12 | -$1.41M derived: sum of 3 quarters · filed 2025-08-12 | -$1.55M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$2.94M 10-Q · filed 2025-05-13 | -$4.65M derived: sum of 2 quarters · filed 2025-05-13 | -$4.80M derived: sum of 3 quarters · filed 2025-05-13 | -$551.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$1.86M derived: sum of 2 quarters · filed 2025-03-26 | $2.39M derived: sum of 3 quarters · filed 2025-03-26 | -$710.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | -$146.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.10M derived: sum of 2 quarters · filed 2024-11-12 | $1.00M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $4.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.15M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$3.10M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $844.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |